Earnings Call · Q3 FY2024·2024-11-13

Q2 21EPS n/a·Rev n/aQ1 21EPS n/a·Rev n/aQ4 20EPS n/a·Rev n/aQ3 20EPS n/a·Rev n/a⚠ consensus missing

Starling Oncology, Inc. DFPH

Mark Hueppelsheuser — General Counsel

Daniel Virnich — Chief Executive Officer

Rob Carter — Chief Financial Officer

no move data

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more DFPH calls or request research access.

More DFPH calls Browse calls Request research access